Antiviral Principles

Viruses depend overwhelmingly on host cell machinery for replication, meaning far fewer genuinely virus-specific molecular targets exist compared to bacteria, where distinct prokaryotic structures, cell wall, 70S ribosomes, provide abundant targets absent from human cells entirely.

Effective antiviral targets are therefore concentrated specifically on the small number of genuinely virus-encoded, virus-specific enzymes and structural proteins that have no close human equivalent in the order they act within the viral replication cycle.

Blocking attachment or membrane fusion prevents the virus from ever entering the host cell at all, the earliest possible point of pharmacological interruption in the entire replication cycle.

HIV fusion inhibitors target gp41-mediated membrane fusion specifically, blocking the final entry step after gp120-CD4 and coreceptor binding has already occurred.

HIV entry inhibitors targeting the CCR5 coreceptor directly, rather than a viral protein, represent a distinct strategy, blocking a host cell target rather than a viral one, exploiting the same CCR5-dependency biology that underlies the CCR5-delta32 natural resistance phenomenon.

Monoclonal antibody prophylaxis against RSV works by the same entry-blocking principle, neutralising the virus's attachment glycoprotein before it can bind the host cell receptor, though functioning as a passive immunoprophylaxis strategy rather than a conventional small-molecule drug.

Blocking release of the viral genome from its capsid after entry was historically the target of an early influenza antiviral class, the adamantanes.

Resistance became widespread among circulating influenza strains. This target class has therefore fallen out of routine clinical use in most contemporary practice. It illustrates the resistance principle.

Viral DNA polymerases (herpesviruses) and RNA-dependent RNA polymerases (many RNA viruses) are frequently targeted by nucleoside or nucleotide analogue drugs. The analogue is incorporated into the growing viral nucleic acid chain in place of the normal building block. This causes chain termination and halts genome replication.

Aciclovir, targeting HSV and VZV DNA polymerase, is the paradigm example of selective toxicity achieved despite acting on a polymerase target.

Aciclovir needs initial phosphorylation by a virus-encoded thymidine kinase before it becomes active. This enzyme is present in infected cells but not functionally equivalent in uninfected human cells.

The drug is therefore preferentially activated within infected cells. This achieves genuine selectivity, even though DNA polymerase has a human cellular counterpart.

Direct-acting antivirals for hepatitis C include agents targeting the HCV-specific RNA-dependent RNA polymerase, alongside other HCV-specific targets. They form part of the combination approach that has made HCV reliably curable.

The defining retroviral enzyme is targeted by two mechanistically distinct antiretroviral drug classes.

• Nucleoside and nucleotide reverse transcriptase inhibitors are chain-terminating analogues. The principle is similar to nucleoside analogue chain termination, but without an equivalent virus-specific activation step.
• Non-nucleoside reverse transcriptase inhibitors bind a distinct site on the enzyme itself. They inhibit its function through an allosteric mechanism rather than chain termination.

Reverse transcriptase has no human cellular equivalent at all, as human cells do not normally copy RNA into DNA. In principle this target offers a genuinely clean selective toxicity profile.

In practice, these drug classes still cause clinical toxicity through other, off-target mechanisms.

Integrase inhibition blocks insertion of the reverse-transcribed viral DNA into the host chromosome, preventing proviral establishment. Integrase strand transfer inhibitors are now a cornerstone component of modern first-line antiretroviral therapy, reflecting both strong antiviral potency and a generally favourable tolerability profile relative to some older antiretroviral classes.

Like reverse transcriptase, integrase has no human cellular equivalent, human cells do not normally integrate foreign DNA into their genome as a matter of standard biology, providing an intrinsically clean target.

Protease inhibition blocks the maturation step in which precursor polyproteins are cleaved into their final, functional structural and enzymatic components. HIV protease inhibitors and HCV protease inhibitors, part of the modern direct-acting antiviral combination regimens for hepatitis C, both exploit this same general target logic, though acting on entirely distinct, virus-specific protease enzymes.

Protease inhibitor activity produces immature, noninfectious virions even when the preceding assembly step has proceeded normally, illustrating that blocking a late-stage process can still fully prevent productive infection, not only blocking early entry or replication steps.

Neuraminidase inhibition blocks release of newly assembled influenza virions from the infected cell surface. Without neuraminidase's sialic-acid-cleaving activity, progeny virions remain aggregated at the cell surface via ongoing haemagglutinin binding. They cannot disseminate to infect further cells.

Neuraminidase inhibitors, oseltamivir and related agents, are most effective when started early in the course of illness. The target acts at the release and dissemination stage, not at initial infection.

Treatment started after substantial viral replication has already occurred therefore has correspondingly less opportunity to alter the course of illness.

Antiviral resistance arises through the same genetic mechanism as viral evolution generally, which is mutation. For HIV specifically, quasispecies diversity and recombination also contribute.

Resistance-conferring mutations typically occur within the drug target itself. Examples are an altered reverse transcriptase, protease or polymerase with reduced drug binding affinity. The enzyme retains sufficient normal function to remain viable.

Resistance risk is generally proportional to a combination of three factors.

• The virus's intrinsic mutation rate. RNA viruses, and HIV specifically, are at higher risk than DNA viruses.
• The size and turnover rate of the actively replicating viral population within the host. Chronic, high-viral-load infections give more opportunity for a resistant variant to arise and be selected than an acute, rapidly cleared infection.
• The selective pressure of suboptimal drug exposure, such as inadequate dosing, poor adherence or monotherapy. Each allows partial viral suppression, which favours emergence of a resistant variant. Complete suppression would prevent ongoing replication and mutation entirely.

Combination therapy is the clinical strategy that exploits a simple statistical logic. Several antiviral agents with distinct resistance pathways are used simultaneously. Simultaneous multidrug resistance within a single viral genome is then statistically far less likely than resistance to any single agent.

The virus would need to independently acquire resistance mutations to every drug in the combination at once.

Combination antiretroviral therapy for HIV is the paradigm example. It typically uses three drugs from at least two different mechanistic classes. This combination strategy transformed HIV from a rapidly progressive, near-uniformly fatal infection into a manageable chronic condition.

Direct-acting antiviral combination therapy for hepatitis C similarly combines agents targeting distinct HCV-specific proteins, including polymerase, protease and other virus-specific targets. The same combination logic achieves reliable cure rates. Here the aim is genuine eradication rather than long-term suppression alone.

Some viruses present a fundamental pharmacological problem. Herpesviruses undergo true transcriptional latency. HIV establishes a latent, dormant reservoir alongside chronic active replication.

Antiviral drugs, without exception across every mechanism covered here, act only on actively replicating virus. They have no effect on a genome that is transcriptionally silent and producing no viral protein for the drug's target to act upon.

This is the mechanistic reason herpesvirus suppressive therapy reduces reactivation frequency but does not eliminate the latent reservoir.

It is also the reason HIV antiretroviral therapy achieves durable viral suppression in blood without achieving cure. The latent proviral reservoir remains undetected and untouched by ongoing treatment. It is ready to reseed active infection immediately on treatment interruption.

Genuine cure of latent and persistent infections therefore needs fundamentally different approaches beyond blocking replication targets. Strategies under active research include:

• Reactivating latent virus to expose it to immune clearance or drug action (shock and kill approaches for HIV).
• Enhancing host immune surveillance to better control or eliminate the reservoir directly.

HCV is different. It lacks an analogous latent reservoir, so complete drug-mediated cure is achievable through sufficiently prolonged and effective suppression of active replication alone.